Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TheraSphere followed by durvalumab + tremelimumab versus TheraSphere alone for unresectable hepatocellular carcinoma
2021-001907-33Phase 2Suspended
- Sponsor
- Boston Scientific Corporation
- Start
- May 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Boston Scientific Corporation. Primary endpoint: Objective response rate. Started May 2022; status: suspended.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2021-001907-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001907-33.